HCW Biologics second quarter 2026 loss hit $5.2M despite $6.7M year-to-date licensing revenue

HCW Biologics reported second quarter 2026 revenue of $0.14 million and a net loss of $5.2 million. While year-to-date performance was bolstered by a significant licensing agreement, the company issued a going concern warning due to its limited cash runway.

Key Highlights

• Preliminary Phase 1 clinical data for HCW9302 in alopecia areata showed a ≥25% reduction in SALT scores for all participants in the second dose cohort.
• Management disclosed substantial doubt regarding the company's ability to continue as a going concern, requiring additional funding beyond current cash levels of $0.74 million.
• The company successfully executed a one-for-six reverse stock split on June 30, 2026, to regain compliance with Nasdaq's minimum bid price requirements.